Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation
Ido Sadras, Eitan Kerem, Galit Livnat, et al.
Journal of Cystic Fibrosis (2023) Vol. 22, Iss. 6, pp. 1062-1069
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis
Hermann Bihler, Andrey Sivachenko, Linda Millen, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 664-675
Open Access | Times Cited: 36
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint
Pierre‐Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 1, pp. 2301959-2301959
Closed Access | Times Cited: 19
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 888-900
Closed Access | Times Cited: 10
CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
Juliet Lefferts, Marlou C. Bierlaagh, Suzanne Kroes, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14539-14539
Open Access | Times Cited: 21
Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
Simon Y. Graeber, Anita Balázs, Niklas Ziegahn, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12365-12365
Open Access | Times Cited: 19
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis
Edith T. Zemanick, I. Emerman, Morgan McCreary, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 676-684
Closed Access | Times Cited: 8
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap
Anneliene Hechtelt Jonker, Elena-Alexandra Tãtaru, Holm Graeßner, et al.
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 40-56
Closed Access | Times Cited: 7
Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
George M. Solomon, Rachel W. Linnemann, Rachel Rich, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 12, pp. 947-957
Closed Access | Times Cited: 5
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation
Bat El Bar Aluma, Joel Reiter, Ori Efrati, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 4, pp. 685-689
Closed Access | Times Cited: 4
Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls
Suzanne Kroes, Marlou C. Bierlaagh, Juliet Lefferts, et al.
Journal of Cystic Fibrosis (2024)
Closed Access | Times Cited: 4
In VitroModulator Responsiveness of 655CFTRVariants Found in People With CF
Hermann Bihler, Andrey Sivachenko, Linda Millen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 11
Co-segregation of the c.489+3A>G variant with p.Cys1400Ter pathogenic CFTR mutation in Cyprus: prevalence and clinical implications
Panayiotis K. Yiallouros, Pinelopi Anagnostopoulou, Panayiotis Kouis, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
Burkhard Tümmler, Sophia T. Pallenberg, Anna‐Maria Dittrich, et al.
Molecular and Cellular Pediatrics (2025) Vol. 12, Iss. 1
Open Access
Comprehensive Assessment of CFTR Modulators’ Therapeutic Efficiency for N1303K Variant
Anna Efremova, N. Kashirskaya, S. Krasovskiy, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2770-2770
Open Access | Times Cited: 3
The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis
Dániel Lupas, Frank Y. Chou, Mohammad Abdullah Al Hakani, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 950-958
Closed Access | Times Cited: 3
Cystic fibrosis year in review 2023
David V. Swetland, Adrienne P. Savant
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3106-3116
Open Access | Times Cited: 3
Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature
Maria Gabriela Tupayachi Ortiz, Nathalie Baumlin, Makoto Yoshida, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26955-e26955
Open Access | Times Cited: 2
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
Pierre‐Régis Burgel
European Respiratory Journal (2024) Vol. 63, Iss. 2, pp. 2400233-2400233
Closed Access | Times Cited: 2
Elexacaftor-Tezacaftor-Ivacaftor Improves Clinical Outcomes in Individuals with CF Encoding N1303K CFTR
George M. Solomon, Rachel W. Linnemann, Rachel Rich, et al.
(2024)
Closed Access | Times Cited: 2
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations
Valentina Fainardi, Federico Cresta, Claudio Sorio, et al.
Pediatric Pulmonology (2024)
Open Access | Times Cited: 2
Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
Michael Dooney, Tarek Saba
European Respiratory Journal (2024) Vol. 63, Iss. 2, pp. 2301392-2301392
Closed Access | Times Cited: 1
Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescue
Iwona Pranke, Valeria Capurro, B. Chevalier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis
Mariane Gonçalves Martynychen Canan, Caroline Souza Sokoloski, Carolina Rossetti Severo, et al.
Archivos de Bronconeumología (2024) Vol. 60, Iss. 8, pp. 526-528
Closed Access | Times Cited: 1
Treatment effects of CFTR modulators on people with Cystic Fibrosis carrying the Q359K/T360K variant
Karin Yaacoby‐Bianu, Moshe Heching, Mordechai R. Kramer, et al.
ERJ Open Research (2024), pp. 00386-2024
Open Access | Times Cited: 1
Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators
Ceren Ayça Yıldız, Merve Selçuk, Şeyda Karabulut, et al.
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3250-3259
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top